0623 GMT - Sanofi is set for a solid 2025, driven by its immunology pipeline with its anti-inflammatory drug Dupixent as its key revenue driver, Berenberg analysts say in a note. The French pharma giant forecasts 14% EPS growth in 2025, excluding its to-be-sold consumer-health business Opella, the analysts say. Sanofi confirmed its guidance for a strong rebound in 2025 and will share its buyback plans at its upcoming Q4 results, they say. Berenberg analysts anticipate key late-stage trial data for its asthma treatment itepekimab and multiple-sclerosis drug tolebrutinib in the second half of the year, they say. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
January 17, 2025 01:23 ET (06:23 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.